OCB are presenting today with IBM at Pharmatec19 – London Room 7 at 11:20: Using AI Technology To Improve Outcomes For Cancer Patients

Today 25 September 2019, OCB are presenting with IBM at Pharmatec19 – London Room 7 at 11:20 – Using AI Technology To Improve Outcomes For Cancer Patients. OCB aim to benefit cancer patients by implementing advanced precision oncology diagnostics. James Otter, CEO and Dr Guy Mozolowski, Head of Research and Development, at Oxford Cancer Biomarkers OCB will discuss how OCB are using IBM AI tools in their transformational technology platform Coloprog to improve colorectal cancer treatment and improve outcomes for cancer patients. http://bit.ly/2l1TsW4

Contact

Oxford Cancer Biomarkers Ltd

Tel:  +44 1865 784743

[email protected]